
Channel Medsystems
Channel Medsystems - bringing innovation to the delivery of women’s healthcare.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
N/A | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor investor investor investor | €0.0 | round | |
$14.1m | Series C | ||
Total Funding | 000k |
USD | 2020 | 2021 |
---|---|---|
Revenues | 0000 | 0000 |
EBITDA | 0000 | 0000 |
Profit | 0000 | 0000 |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Cerene is a medical technology company specializing in innovative treatments for heavy menstrual bleeding. The company's flagship product is a cryotherapy device designed to ablate the endometrial lining of the uterus in premenopausal women who have completed childbearing. This treatment is performed in the comfort of a doctor's office without the need for general anesthesia, making it a convenient and less invasive option for patients. Cerene primarily serves women suffering from heavy menstrual bleeding due to benign causes, aiming to improve their quality of life by offering a safe, effective, and cost-efficient solution. The company operates in the healthcare market, focusing on gynecological treatments. Cerene's business model involves selling its cryotherapy devices to healthcare providers, who then offer the treatment to patients. Revenue is generated through the sale of these devices and potentially through follow-up services and support. The company is committed to empowering women to take control of their health journeys by providing innovative and accessible medical technologies.
Keywords: cryotherapy, endometrial ablation, heavy menstrual bleeding, premenopausal women, gynecology, in-office treatment, medical device, patient comfort, healthcare, innovative technology.